Multiple plasma proteins and systemic pathways

The term Multiple plasma proteins and systemic pathways does not refer to a single molecular target but rather a broad category of therapeutic interventions that interact with the complex mixture of proteins found in human plasma. This classification is often used for plasma-derived therapies like intravenous immunoglobulin (IVIG) or albumin, which exert their effects through hundreds of distinct protein-protein interactions and the modulation of systemic physiological networks (NIH StatPearls, 2023). These therapies are essential for managing conditions where systemic homeostasis is disrupted, such as in severe immunodeficiencies, inflammatory polyneuropathies, or critical fluid loss (PubMed, 2022). Because this target encompasses a wide array of proteins—including antibodies, transport proteins, and coagulation factors—the pharmacological response is multi-faceted. For instance, while one component may provide passive immunity, another may regulate osmotic pressure or inhibit inflammatory cascades. This systemic approach is distinct from targeted small-molecule or monoclonal antibody therapies that focus on a single receptor or enzyme (Wikipedia, 2024). Consequently, monitoring efficacy often requires broad systemic biomarkers rather than a single molecular readout.

Other names

Plasma protein poolSystemic physiological pathwaysCirculating plasma proteinsPlasma-derived therapeutic targets

The mechanism of action is pleiotropic and depends on the specific plasma-derived product; for example, intravenous immunoglobulin (IVIG) works by neutralizing circulating autoantibodies, modulating cytokine production, and blocking Fc receptors on macrophages (StatPearls, 2023). Albumin acts by increasing intravascular oncotic pressure and binding various endogenous and exogenous substances (PubChem, 2024).